Lv1
40 积分 2022-07-13 加入
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
3小时前
待确认
Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II clinical trial
6个月前
已完结
First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial
8个月前
已完结
Hepatic arterial infusion chemotherapy combined with toripalimab and surufatinib for the treatment of advanced intrahepatic cholangiocarcinoma
8个月前
已关闭
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma
10个月前
已完结
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET)
10个月前
已完结
Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II clinical trial
1年前
已完结
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study
2年前
已完结
Combination chemotherapy with NAB ® ‐paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP‐CAPABIL Pilot Study)
2年前
已完结
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated by Gemcitabine-based Chemotherapy
2年前
已完结
皖公网安备34019202002308
